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Cyclooxygenase-2 (COX-2) is an inducible enzyme expressed at sites of inflammation and in cancer. As such, 
COX-2 is the therapeutic target for nonsteroidal anti-inflam-
matory drugs (NSAID) that include ibuprofen, diclofenac, and 
celecoxib. NSAIDs are among the world’s most consumed med-
ications to treat pain and inflammation, with an estimated 30 bil-
lion doses consumed annually in the United States.1 NSAIDs 
can also prevent cancer with prospective clinical trials reporting 
that celecoxib prevents ≈50% of colon cancers in susceptible 
individuals.2 The greatest limitation in the therapeutic use of 
NSAIDs is their cardiovascular and renal safety profile. Indeed, 
NSAIDs are an independent risk factor for cardiovascular 
events, and concern surrounding their cardiovascular side effects 
has virtually arrested new drug development and led to a failure 
to realize the full potential of blocking COX-2 for cancer pre-
vention. Thus, there is an urgent need to understand how COX-2 
protects the cardiovascular system. It was initially thought that 
cardiovascular side effects were limited to drugs that selectively 
target COX-2,3,4 such as Vioxx (rofecoxib) and Celebrex (cele-
coxib), which were introduced in the early 2000s.5 However, 
as a result of subsequent epidemiology analyses6 and 2 large 
recent clinical cardiovascular outcome studies, SCOT (Standard 
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Care Versus Celecoxib Outcome Trial)7 and PRECISION 
(Prospective Randomized Evaluation of Celecoxib Integrated 
Safety vs Ibuprofen or Naproxen),8 it is clear that traditional 
NSAIDs, including ibuprofen, carry at least as great a cardio-
vascular and renal risk as the COX-2 selective drug celecoxib.
The mechanisms by which NSAIDs produce their car-
diovascular side effects remain hotly debated, but underlying 
causes include increases in thrombosis, atherosclerosis, and 
blood pressure. There is agreement in the field that cardiovas-
cular side effects of NSAIDs involve loss of key protective 
downstream prostaglandins.9,10 These include (1) prostacyclin, 
a vasodilator and antiplatelet hormone that acts via classical cell 
surface I-prostanoid (IP) receptors to increase cAMP and the 
nuclear receptor PPARβ/δ (peroxisome proliferator-activated 
receptor-β/δ) to signal with both genomic and nongenomic 
pathways and (2) prostaglandin E2 (PGE2) that can also cause 
vasodilation through cAMP via EP2 and EP4 receptors.11 There 
is also agreement in the field that cardiovascular side effects of 
NSAIDs occur via inhibition of constitutively expressed COX-2 
because the relative risk is the same (1.3) in those with cardio-
vascular/inflammatory disease as in people without systemic 
inflammatory disease (eg, healthy individuals or patients with 
osteoarthritis or at risk of colon cancer) and can be modeled in 
healthy mice9,10 in the absence of local or systemic inflammation. 
What remains contentious is the precise site of cardioprotective 
constitutive COX-2. Is it throughout the systemic endothelium 
as some suggest10 or is it in the kidney?12 The case for pan-
endothelial COX-2 is supported by studies measuring urinary 
levels of the prostacyclin metabolite, PGIM (prostaglandin 
I-metabolite [2,3-dinor-6-keto-prostaglandin F1ɑ]) , and tissue-
specific COX-2 knockout mice. However, generalized endothe-
lial COX-2 expression is not present in healthy blood vessels 
from humans13 or mice,14–16 and PGIM can originate from the 
kidney.17 The case for a renal COX-2 is supported by a clear 
body of evidence showing COX-2 is constitutively expressed 
in the kidney12 via NFAT (nuclear factor of activated T-cells)-
mediated transcription18 and the contribution of renal COX-2 
to regulation of (1) blood pressure,12 (2) the renin–angiotensin 
system, and (3) specific vasomotor gene pathways, including 
the endogenous NO synthase inhibitor ADMA (asymmetric 
dimethylarginine).9 In line with this, NSAIDs also reduce renal 
blood flow as a direct result of blocking COX-2.12,19,20 Indeed, it 
has been suggested that, on a population basis, the magnitude of 
blood pressure21 or circulating ADMA elevation9 produced by 
COX-2 inhibitors is entirely sufficient to explain the cardiovas-
cular side effects produced by NSAIDs.
Given the importance of constitutive COX-2 to our 
understanding of the cardiovascular and renal side effects of 
NSAIDs, in the present study, we have addressed its role in 
the control of regional blood flow for a wide range of tissue 
sites, including the kidney. We have done this by determining 
the effect of acute COX-2 inhibition on local regional blood 
flow throughout the body and mapped this to the distribution 
of COX-2 across the same tissues.
Methods
The authors declare that all supporting data are available within the 
article and its online-only Data Supplement. A full methodology is 
provided in the online-only Data Supplement. Briefly, regional blood 
flow was measured in wild-type mice using a microsphere deposition 
method,22 before and 20 minutes after administration of the selective 
COX-2 inhibitor, parecoxib (5 mg/kg; IV; Pfizer). In parallel, COX-2 
expression was mapped using bioluminescent imaging of tissue from 
COX-2 luciferase reporter mouse (Cox2fLuc/+).23 Kidney and spleen 
prostaglandin, cAMP, and cGMP content were measured in homoge-
nates by immunoassay and gene expression by quantitative polymerase 
chain reaction. Vascular responses were measured by wire myography, 
and in small intrarenal arcuate arteries, using a novel technique of 
video imaging in live precision-cut kidney slices based on early studies 
using lung.24,25 Experiments were performed on male, 8-week-old mice 
after ethical review and in accordance with local/national guidelines.
Statistics and Data Analysis
Data are presented as means±SE for n experiments. Data were sta-
tistically analyzed using Prism 7 software (Graphpad Software) as 
defined in figure legends—typically either Student unpaired t test or 
2-way ANOVA—and considered significant where P<0.05.
Results and Discussion
Regulation of Regional Blood Flow In Vivo by 
Constitutive COX-2
In this study, we applied the microsphere deposition technique 
of regional blood flow measurement22,26,27 to determine in an 
unbiased way the relative contribution of constitutive COX-2 
to vascular control in the kidney compared with the rest of the 
body (Figure 1A). To do this, we chose a model of acute phar-
macological COX-2 inhibition which allows the role of prosta-
glandin generation on vascular function to be evaluated without 
the confounding effects on renal function that long-term COX-2 
inhibition causes. Although the role of COX-2 may vary in 
disease, we specifically chose to perform our experiments in 
healthy adult mice because this model has been used to mecha-
nistically define the key cardioprotective functions of COX-2 in 
the absence of inflammation, including restraining thrombotic 
tone,10 and maintaining blood pressure and preserving endothe-
lial and renal functions.9 Moreover, although COX-2 is readily 
induced in tissues by physiological stress12 or systemic inflam-
mation28 (but only modestly in atherosclerosis29), cardiovascular 
side effects of NSAIDs occur in people with a range of varied 
disease pathogeneses, including colon cancer and osteoarthritis, 
that are not associated with systemic inflammation.5,6
At the dose used, parecoxib produced >90% COX-2 inhibi-
tion without detectable COX-1 inhibition when assessed by ex 
vivo bioassay (Figure S1 in the online-only Data Supplement). 
As has been shown before, blocking COX-2 activity with acute 
systemic parecoxib administration resulted in a clear and pro-
found reduction in basal blood flow in both the renal medulla 
and cortex (Figure 1A). COX-2 inhibition also reduced blood 
flow in spleen, adipose tissue, and testes; however, in the 
majority of tissues, parecoxib had no effect on local blood 
flow (Figure 1A). In agreement with the localized nature of the 
changes in blood flow, parecoxib did not alter systemic blood 
pressure, heart rate, cardiac output, or total peripheral vascular 
resistance (Figure 2), which also supports the idea that blood 
flow reductions are because of loss of local COX-2–driven 
prostanoids and do not reflect changes in juxtaglomerular feed-
back-driven angiotensin II or other circulating pressors.
We next mapped regional COX-2–driven blood flow 
onto the pattern of constitutive COX-2 expression in tissues 
using Cox2fLuc/+ reporter mice. Although we have previously 
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reported regional COX-2 expression in some tissues using this 
approach,15,18 here we have extended this array to match the full 
panel of structures where blood flow was studied (Figure 1B). 
As we have shown previously, constitutive COX-2 expression 
was observed in healthy tissue in the absence of inflammation 
in the renal medulla, skin, thymus, colon, and brain (Figure 1B). 
Notably, the strong expression in the renal medulla correlates 
closely with the powerful effect of COX-2 inhibition on blood 
flow in this region. However, in other tissues, no such overlap 
was seen. For example, although the brain and gut showed 
strong constitutive COX-2 expression, COX-2 inhibition pro-
duced no local change in blood flow at these sites indicating that 
the link between COX-2 expression and blood flow control is 
complex and perhaps reflects the degree of COX-2 activation, 
the cell types expressing the enzyme, and the prostanoids they 
produce. Conversely, and perhaps more surprisingly, in the renal 
cortex, spleen, adipose tissue, and testes, where blood flow was 
reduced by COX-2 inhibition, minimal local COX-2 expression 
was observed in luciferase reporter mice. In the case of the renal 
cortex, this may be explained by the vascular architecture of the 
kidney where blood enters the organ through the COX-2–rich 
medulla region, from where it may carry prostanoids into the 
cortex. In the spleen, adipose, and testes, however, the effect of 
parecoxib on blood flow is more difficult to explain. It is unlikely 
to reflect the sensitivity of the reporter mouse imaging tech-
nique used to detect COX-2 expression as we have previously 
demonstrated this approach has similar or greater sensitivity to 
antibody-based protein detection and activity measurement.15,23
Figure 1. Effect of cyclooxygenase-2 (COX-2) inhibition on regional blood flow (A) and level of constitutive enzyme expression (B). 
Blood flow was measured using a microsphere deposition technique basally and after COX-2 inhibition by parecoxib (5 mg/kg IV). 
COX-2 expression was measured by bioluminescent imaging of tissue from Cox2fLuc/+ mice. Inset panels show representative images 
with luminescent signal with the scale red (highest) > black (lowest). Data are presented as mean±SE. *P<0.05 by Student unpaired t 
test. n=5 to 6.
Figure 2. Effect of acute cyclooxygenase-2 inhibition on heart rate (A), mean arterial blood pressure (B), cardiac output (C), and total 
peripheral vascular resistance (D). Heart rate and blood pressure were measured by carotid artery cannulation, cardiac output from 
microsphere ejection rate, and total peripheral resistance calculated. Data are presented as mean±SE. *P<0.05 by Student unpaired t 
test. n=5 to 6.
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COX-2 Expression and Activity Within Tissues
In the case of the spleen and testes, solid tissues in which bio-
luminescence imaging may be limited by tissue penetrance, 
we reasoned that internal structures may express sufficient 
COX-2 to control local blood flow regulation. To explore this 
possibility, we performed a study using a range of solid tis-
sues from Cox2fLuc/+ mice, in which luminescence was imaged 
from both the tissue surface (as in Figure 1) and in tissue 
bisected to reveal internal structures (Figure 3A); like we have 
done for the kidney and heart in our previous work. As we 
have shown previously,15,18 bisecting the kidney to reveal the 
medulla region produced ≈20-fold increase in detected Cox2 
promoter-driven bioluminescence. In spleen and testes, how-
ever, the effect of tissue division was negligible, indicating 
that in these tissues, COX-2 is essentially absent (Figure 3B).
To further exclude the possibility that these organs might 
contain local COX-2 activity undetectable by reporter mouse 
tissue imaging, we measured prostacyclin and PGE2, the best 
established vasodilator prostanoids, as functional readouts of 
COX-2 activity. We focused our analysis on the spleen and 
used the renal medulla as a positive control for a tissue with 
high constitutive COX-2 expression. Wild-type mice treated 
with parecoxib in vivo to block COX-2 activity had reduced 
prostacyclin and PGE2 in the renal medulla (Figure 3B and 
3C), confirming the effectiveness of parecoxib and what 
we know of COX-2 expression in this tissue. By contrast, 
parecoxib had no effect on prostacyclin or PGE2 content in 
the spleen (Figure 3D and 3E). In this regard, the pathways 
regulating blood flow in the spleen, adipose, and testes remain 
unclear and beyond the scope of this investigation. One pos-
sibility is that regulation of blood flow in these regions is a 
function of COX-2 expressed in the brain. For example, in the 
spleen, it is known that blood flow is under tonic control by 
sympathetic activity and that conditions which increase cen-
tral COX-2 expression increase splenic blood flow via neural 
activation.30
Taken together, these data demonstrate that the kidney 
is the only site in the body where local constitutive COX-2 
expression impacts on vascular function. Our observation 
that COX-2 inhibition selectively effects the renal vascula-
ture while having little to no effect on the majority of vascular 
beds adds to several existing lines of evidence to suggest the 
kidney rather than the systemic vasculature is the major site 
where constitutive COX-2 is locally active within the cardio-
vascular system.14,15,18 As such, it supports the idea that renal, 
rather than generalized endothelial/vascular, expression can 
for account the cardioprotective effects of constitutive COX-
2. This, in turn, may help explain why COX-2 inhibition 
by NSAIDs is harmful to the cardiovascular system even in 
healthy mice and patients who do not have systemic inflam-
mation. This applies not only to control of blood pressure and 
renal function but also in the absence of clear evidence that 
COX-2 is expressed and active in the systemic vasculature, 
inhibition of renal COX-2 may also provide an explanation 
for increase thrombotic events seen in people taking COX-2 
inhibitors given the close links between blood pressure, circu-
lating renal hormones, and systemic vascular disease as previ-
ously suggested.9,21
Figure 3. Level of cyclooxygenase-2 (COX-2) expression within tissues (A) and prostaglandin levels in homogenates of renal medulla 
(B and C) and spleen (D and E) from parecoxib-treated mice. COX-2 expression was measured by bioluminescent imaging of tissue 
from Cox2fLuc/+ mice. Inset panels show representative images with luminescent signal with the scale red (highest) > black (lowest). 
Prostacyclin (measured as 6 ketoPGF1α[6-keto prostaglandin F1ɑ]) and prostaglandin E2 (PGE2) levels in homogenates. Data are 
presented as means±SE. *P<0.05 by Student unpaired t test. n=5 to 6.
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Role of COX Isoforms and Prostanoids in Renal 
Arterioles In Situ
As the main site where COX-2 controls blood flow, we went 
on to explore the associated downstream mechanisms regulat-
ing renal vascular function. To do this, we devised a novel 
approach to measure responses of small arcuate arteries in 
situ, by video microscopy, in precision-cut organotypic kid-
ney slices. The use of precision-cut organ slices, where cel-
lular integrity and biological function are maintained, is 
routine in toxicological studies.31 Furthermore, our group and 
others have used video imaging to monitor real-time vascular 
responses in lung slices.24,25 However, to our knowledge, this 
is the first time this approach has been applied to renal vas-
cular responses. Arcuate arteries are the smallest renal arte-
rial vessels identifiable using this technique. Because of their 
position within the renal vascular tree, these vessels contribute 
both to renal blood flow regulation and glomerular filtration. 
We compared responses in these vessels to those in isolated 
segments of the main renal artery and aorta, for which we used 
traditional myography.
Isolated blood vessels do not spontaneously develop tone. 
Therefore, to determine whether COX products influence vas-
cular tone ex vivo, vessels were contracted with phenyleph-
rine, a selective α1-adrenoceptor agonist, in the presence and 
absence of diclofenac, a nonselective NSAID which blocks 
both COX-1 and COX-2–dependent prostanoid formation. 
Phenylephrine induced concentration-dependent contraction of 
aorta (Figure 4A), renal artery (Figure 4B), and arcuate arteries 
(Figure 4C). In arcuate arteries, but not aorta or renal arteries, 
diclofenac increased the potency of phenylephrine, suggesting 
that, for small arteries within the kidney but not in the main 
renal artery or aorta, COX products functionally antagonize 
contraction basally. The effect of diclofenac on phenylephrine 
responses in arcuate arteries was reproduced with the active 
metabolite of parecoxib, valdecoxib (Figure 4D and 4E), but 
not with the COX-1 inhibitor, SC560 (Figure S2) at concentra-
tions which produce selective inhibition of COX-232 and COX-
1,33 respectively. These data confirm that COX-2 is the active 
COX isoform responsible for regulation of inhibitory vascular 
responses in arcuate arteries and reflect analogous observa-
tions on COX-2 control of blood flow in the kidney in vivo 
(Figure 1). They also fit with our previous findings that neither 
aorta nor the large renal artery constitutively express COX-2.15 
Regulation of renal vascular function by COX-2 may reflect 
both autocrine actions of vascular prostanoids and paracrine 
actions of prostanoids produced by nonvascular cells in the 
kidney, where constitutive COX-2 expression predominates in 
specific tubular and interstitial cell types.12
PGE2 and prostacyclin are the most abundant COX 
products produced by renal tissue.34 Both mediators can 
Figure 4. Effect of cyclooxygenase (COX) inhibition on contractile responses of aorta (A), renal artery (B), and intrarenal arcuate arteries 
(C–E). Contractile responses to phenylephrine were studied in aorta and renal artery by wire myography with and without nonselective COX 
inhibition by diclofenac (3 μmol/L; A and B) and in intrarenal arcuate arteries by imaging in precision-cut kidney slices with and without 
diclofenac (C) or the selective COX-2 inhibitor valdecoxib (D; 3 μmol/L). Inset panels (E) show example images of the effect of phenylephrine 
(basal vs 1 μmol/L) on arcuate arteries in the absence (veh) and presence of valdecoxib (valde). Data in A and B are expressed normalized to 
the response produced by a high potassium physiological salt solution (KPSS). *P<0.05 by 2-way ANOVA. n=4 to 6.
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vasodilate some but not all vessels. Isolated renal medulla 
and renal cortex, as well as aorta, produced ≈4- to 5-fold 
more prostacyclin compared with PGE2 (Figure S3). 
However, neither PGE2 nor the prostacyclin analogue trepro-
stinil relaxed the aorta (Figure 5A) or the main renal artery 
(Figure 5B). Indeed, PGE2 contracted both vessels. This 
is consistent with what is known about prostanoid signal-
ing in large vessels, where the balance of vasodilator (IP, 
EP2, EP4) and vasoconstrictor (EP1, EP3, TP) prostanoid 
receptors is such that responses to prostanoid vasodilators 
are minimal.35 In contrast, in arcuate arteries, PGE2 had no 
effect while treprostinil produced clear and consistent dilator 
responses (Figure 5C). Treprostinil, as with authentic pros-
tacyclin, activates 2 receptors: (1) the cell surface IP linked 
to adenylate cyclase and cAMP signaling and (2) the nuclear 
receptor PPARβ/δ linked to both genomic and nongenomic 
pathways.11,36 When measured by quantitative polymerase 
chain reaction, the genes encoding IP and PPARβ/δ were 
both expressed throughout the kidney, with PPARβ/δ being 
more abundant (Figure S3). To understand how activation of 
these receptors contributes to renal vasomotor responses, we 
used 2 selective agonists: MRE269 that activates IP recep-
tors and GW0742 that activates PPARβ/δ receptors. Both 
drugs produced vasodilation of arcuate arteries (Figure 6A) 
but, as with treprostinil, neither had effects in aorta or the 
main renal artery (Figure S4).
Role of Specific Prostacyclin Receptors in Renal 
Vascular Responses
To better understand the relative contribution of IP and 
PPARβ/δ pathways to endogenous COX-2–dependent renal 
blood flow regulation in vivo, we measured cAMP levels in 
the renal medulla of mice treated with parecoxib as a marker 
of IP receptor activation. Parecoxib treatment had no effect 
on renal levels of cAMP (vehicle: 12.9±5.0 pmoles/g tissue; 
parecoxib: 14.5±3.7 pmoles/g tissue; P=0.81; n=6–8) or related 
cGMP (vehicle: 6.3±0.8 pmoles/g tissue; parecoxib: 3.9±1.1 
pmoles/g tissue; P=0.10; n=6–8). Consequently, we reasoned 
that PPARβ/δ, rather than IP signaling, is the primary driver 
of the renal COX-2/prostacyclin dilator pathway. This idea has 
not previously been proposed, but there are precedents in other 
systems. For example, PPARβ/δ can produce acute signaling 
responses through nongenomic pathways, including direct asso-
ciation with PKCα (protein kinase C α), and transrepression of 
BCL-6 (B cell-lymphoma 6).11,36,37 PPARβ/δ agonists can also 
induce vasodilation in pulmonary vessels,38 and PPARβ/δ, rather 
than IP receptors, can account for other responses caused by 
prostacyclin drugs in fibroblasts39 and platelets.37 Furthermore, 
PPARβ/δ is known to be active in the kidney, where it protects 
against ischemia/reperfusion injury.40 However, its role in renal 
vasomotor responses to endogenous COX-driven dilator func-
tion has not previously been investigated.
To test the idea that prostanoid-mediated activation 
PPARβ/δ is responsible for renal arcuate artery dilation, we 
compared responses of arcuate arteries in kidney slices from 
wild-type and PPARβ/δ-deficient mice (Ppard−/−; Figure 6B). 
Consistent with our hypothesis, phenylephrine was more 
potent for contraction of arcuate arteries in kidney slices from 
mice lacking PPARβ/δ than those from wild-type mice. This 
was validated pharmacologically, with a similar potentiation of 
the responses to phenylephrine observed when arcuate arteries 
in kidney slices from wild-type mice were pretreated with the 
highly selective PPARβ/δ antagonist, GSK3787 (Figure 6C). 
In addition, when PPARβ/δ function was disrupted by either 
genetic deletion or treatment with GSK3787, responses were 
not further enhanced by blocking endogenous COX-2 activ-
ity (with diclofenac or valdecoxib), suggesting that PPARβ/δ 
activation accounts for the majority of the vasodilator tone 
produced by constitutive COX-2 activity in these vessels 
(Figure 6B–6E). PPARβ/δ has previously been suggested to 
regulate activity of NFAT transcription factors41 which con-
trol renal COX-2 expression.18 To exclude the possibility that 
altered prostanoid production or receptor expression could 
complicate interpretation of the results, we studied renal pros-
tacyclin and PGE2 levels and expression of COX-2, IP, and 
EP1-4 receptor mRNA levels and found no difference between 
Ppard−/− and control animals (Table S2). Thus, the effect of 
PPARβ/δ disruption on arcuate artery contractility reflects its 
contribution to prostanoid sensing rather than a confounding 
dysregulation of the prostanoid pathway in these mice.
Summary and Conclusions
COX-2 is expressed constitutively in multiple discrete regions 
of the body, including the brain, gut, and kidney. Other organs, 
Figure 5. Effect of treprostinil and prostaglandin E2 (PGE2) on vascular tone in the aorta (A), renal artery (B), and intrarenal arcuate arteries 
(C). Responses to the prostacyclin analogue treprostinil and PGE2 were measured in precontracted vessels by wire myography (A and B) 
or precision-cut kidney slice imaging (C). *P<0.05 by 1-way ANOVA. n=4 to 6.
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such as the heart, show negligible expression. Within the 
sites of constitutive COX-2 expression we have identified, 
our data demonstrate the only place where local constitu-
tively expressed COX-2 regulates blood flow is the kidney. As 
summarized in Figure S5, regulation of renal blood flow by 
COX-2 activity occurs through a vasodilator pathway involv-
ing prostacyclin acting on PPARβ/δ receptors, a pathway that 
to our knowledge has not previously been described. These 
data highlight the increasingly recognized role that renal 
COX-2 plays in systemic vascular protection and support the 
idea that the kidney rather than the systemic circulation is the 
major site of constitutive COX-2 expression where inhibition 
by NSAIDs could produce cardiovascular side effects. They 
also suggest that in the future, drugs that target inflammatory/
oncogenic prostanoid signaling but spare the renal COX-2/
PPARβ/δ might have improved cardiovascular and renal safety 
compared with NSAIDs. In a more general context, the find-
ings of this study may have direct relevance to the mechanistic 
understanding of renal disease, where for example, a loss of 
COX-2, prostacyclin, or PPARβ/δ could contribute to reduc-
tions in medullary blood flow and renal ischemia. Conversely, 
if cancer risks can be overcome, targeting the PPARβ/δ path-
way directly may offer a means to produce selective renal 
vasodilation and offer a potential treatment strategy for acute 
renal failure and other conditions characterized by excessive 
renal vascular tone.
Perspectives
NSAIDs work by blocking COX-2 and are among the most 
widely used medicines worldwide. However, they produce 
serious cardiovascular side effects that have had far-reaching 
effects, including drug withdrawals and increased regulation, 
limiting development of new drugs in this class, and prevent-
ing use of COX-2 inhibitors in cancer prevention. Therefore, 
there is now an urgent unmet need to identify mechanistic 
pathways regulating these cardiovascular side effects. This 
study specifically identifies the kidney as being the sole ana-
tomic site where local constitutive COX-2 drives vascular 
homeostasis and implicates a novel prostacyclin signaling 
pathway. Ultimately, this knowledge will foster development 
of new, safer drugs that spare protective COX-2–driven path-
ways in the vasculature.
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Figure 6. Effect of specific I-prostanoid and PPARβ/δ (peroxisome proliferator-activated receptor-β/δ) agonists (A) and PPARβ/δ gene 
deletion (B and D) or pharmacological blockade (C and E) on responses of intrarenal arcuate arteries. Responses to the I-prostanoid 
agonist MRE269 and to the PPARβ/δ agonist GW0742 were measured in precontracted arcuate arteries studied by precision-cut kidney 
slice imaging. Contractile responses to phenylephrine in intrarenal arcuate arteries were measured in precision-cut kidney slices from 
wild-type and PPARβ/δ knockout mice, with or without diclofenac (B, 3 μmol/L) and in wild-type kidney slices preincubated with the 
selective PPARβ/δ antagonist, GSK3787 (3 μmol/L), with or without valdecoxib (C, 3 μmol/L). Inset panels show example images of the 
effect of phenylephrine (PE; basal vs 1 μmol/L) on arcuate arteries in wild-type and PPARβ/δ knockout mice (D) or in wild-type vessels 
pretreated with GSK3787 (E). *P<0.05 by 1-way ANOVA (A) or 2-way ANOVA (B). n=4 to 10.
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What Is New?
•	We show that the kidney is essentially the only location where cyclooxy-
genase-2 has a vasomotor function, and using a novel technique of mea-
suring vascular function in living kidney slices delineate a tonic prosta-
cyclin/PPARβ/δ (peroxisome proliferator-activated receptor-β/δ)–driven 
renal vasodilator pathways through which this occurs.
What Is Relevant?
•	These data directly dispel the commonly held idea that cyclooxygenase-2 
is expressed throughout the circulation to produce vasodilator prostacy-
clin and local vascular control and have direct relevance to our under-
standing of how cyclooxygenase-2 controls blood pressure and vascular 
health.
Summary
In light of these findings, we must now look to the kidney rather 
than the systemic vasculature if we are to understand the cardio-
vascular side effects caused by nonsteroidal anti-inflammatory 
drugs.
Novelty and Significance
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Supplementary Methods 
 
Animals  
Experiments were performed on 8 week old male mice on a C57Bl/6 background. 
Wild-type mice were purchased from Charles River (UK) or the Biologic Science 
Institute (CEBIO, Federal University of Minas Gerais, Brazil) and used with 
pharmacological inhibitors for the majority of studies described. For other specific 
studies the following genetically modified strains were used: Cox2fLuc/+ mice1 which 
carry a firefly luciferase reporter gene knocked in to the COX-2 locus, Pppard-/- mice2 
which carry a global deletion of PPARβ/δ, and Cox2-/- mice3 which carry a global 
deletion of COX-2. Each were generated and bred as previously described and where 
appropriate, compared to wild-type littermates from each line. Cox2fLuc/+ mice were 
used for COX-2 imaging studies and Pppard-/- mice were used for measuring renal 
vascular responses. Neither strain carries a known renal or other developmental 
phenotype. Cox2-/- mice were used only to as part of the ex vivo bioassay system for 
measuring COX inhibitory activity of plasma because their well-established renal 
developmental defects would confound interpretation of their renal vascular 
responses.  
 
All animals were housed with 12 hr light/dark cycles with free access to food and water. 
All animal procedures were performed in line with EU directive 2010/63/EU and the 
NIH Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, 
revised 1996) after local ethical approval by Imperial College Animal Welfare Ethical 
Review Panel (license no. 70/8422), Federal University of Minas Gerais Animal Care 
Committee, University of California Los Angeles Animal Research Committee 
(protocol no. 1999-066-32) or the Nanyang Technological University and SingHealth 
Institutional Animal Care and Use Committees  in Singapore (IACUC SHS-868).  
 
Microspheres  
Regional blood flow was measured in mice using a microsphere deposition technique4, 
5 modified as we have previously described6 to determine the acute effects of COX-2 
inhibition. Blood flow was studied before, and 20 mins are administration of the COX-
2 inhibitor, parecoxib (5mg/kg i.v.; Pfizer, USA). This time point was carefully selected 
as, after i.v. administration, this is sufficient time to ensure the drug was distributed 
around the body and equilibrated with COX-2 enzymes to produce acute inhibition of 
COX-2-derived prostanoid production7, 8. More chronic dosing protocols, as well as 
Cox2-/- mice were deliberately avoided as chronic loss of COX-2 function produces 
secondary effects such as changes in gene expression and vascular hormone levels 
and life-long loss of COX-2 in knockout mice results in profound developmental 
defects in the kidney. Therefore, this model of acute COX-2 inhibition was used as a 
way to study the effects of local, acute prostanoid production in different vascular beds, 
without the confounding effects of chronic blockade such as increases in circulating 
ADMA level and renal endothelin gene expression impacting on results.  
 
Mice were anaesthetised with urethane (1.2g/kg i.p.; Sigma, Germany). The left 
femoral artery and vein were cannulated for blood withdrawal and drug administration, 
respectively. The right femoral artery was cannulated for measurement of blood 
pressure and heart rate (Biopac Systems Inc, USA), and the left cardiac ventricle 
cannulated via the left carotid artery for administration of microspheres. Once 
instrumented, mice were left to stabilise for 10 mins, before administration of yellow-
 3
green 15μm polystyrene microspheres via the left ventricle (60,000; Life Technologies, 
UK). Simultaneously, a reference arterial blood sample was drawn at a constant rate 
by syringe pump. Mice were then treated with parecoxib (5mg/kg i.v.; Pfizer, USA) and 
after 20 mins, crimson 15μm polystyrene microspheres (60,000; Life Technologies, 
UK) were administered and another reference blood sampled taken as before. 
Animals were next killed by cervical dislocation and tissues of interest dissected for 
analysis. Tissues were dissolved in ethanolic KOH (4M, 50°C; Sigma, Germany), 
microspheres isolated by centrifugation and the fluorescence extracted in ethyl 
acetate (Sigma, Germany). The fluorescence intensity of the extract was measured 
by fluorimetry (Cary Eclipse, Varian, Australia) and blood flow calculated by 
comparison to the appropriate reference blood sample according to the formula:  
 
Tissue blood flow (ml/min/mg) = (Fluorescence of tissue) / (Fluorescence extracted 
from 1ml blood withdrawn at 1ml/min) * Mass of tissue  
 
To confirm that repeat sampling in the same animals did not influence blood flow 
measurement, in a separate study, blood flow was measured before and after saline 
administration. Results presented in Table S1 confirm that repeat measurement had 
no effect of blood flow in any tissue except the stomach. 
 
COX-2 expression using luciferase imaging 
Bioluminescent imaging from Cox2fLuc/+ tissue was performed as previously 
described9. These animals have the coding region of the firefly luciferase gene 
knocked in to the Ptgs2 locus such that luciferase is produced under the control of the 
native Ptgs2 promoter. Measuring COX-2 using this reporter mouse strain is more 
sensitive than detection of COX-2 expression using PCR and antibody-based 
techniques, allows accurate quantification of relative expression without confounding 
effects of RNA/protein extraction and retains the spatial distribution of COX-21, 9. Mice 
were killed by cervical dislocation, tissues of interest were dissected and bathed in D-
luciferin solution (15mg/ml; PerkinElmer, USA) for 30 seconds then immediately 
imaged over 3 mins using a IVIS imaging system (Xenogen, USA). Where indicated, 
solid tissues were bisected along their midline using a scalpel blade and arranged so 
that the cut surface was exposed during imaging. Image data was analysed using 
Living Image software (Xenogen, USA) and quantified as peak photon emission per 
tissue – because this is independent of total tissue amount, it allows comparison 
between tissues of different sizes. 
 
Ex vivo COX activity assays  
The effectiveness and selectivity of parecoxib administered in vivo was assessed by 
ex vivo bioassay of plasma10. Because COX-2 activity in the body is scarce and so the 
effects of COX-2 inhibitors on prostaglandin production in vivo difficult to measure, we 
have previously established an ex vivo assay where the ‘COX inhibitory activity’ of 
plasma can be assessed10. Simply, this determines whether levels of a drug in the 
plasma after in vivo dosing are sufficient to produce COX-1/COX-2 inhibition when 
applied to test systems outside the body. Although the drug used here, parecoxib is a 
selective COX-2 inhibitor, we also studied effects on COX-1 because the COX-1/COX-
2 selectivity of all NSAIDs is relative, and we wanted to exclude the possibility that the 
dose used was also producing inadvertent COX-1 inhibition which would have 
confounded the interpretation of the data.  
 
 4
To do this, plasma from mice treated with parecoxib in vivo as above was incubated 
ex vivo with two test systems. The first was segments (2x2x2mm) of Cox2-/- mouse 
lung – this is a system where only COX-1 is expressed (because COX-2 has been 
deleted). The second was J774 murine macrophage cells (ATCC, USA) treated with 
LPS (24 hrs; 10µg/ml; Sigma, UK) - this is a system where only COX-2 is expressed 
because it is induced by the LPS. Plasma was incubated with test systems for 30 mins 
before stimulation with A23187 Ca2+ ionophore (30μM; Sigma, UK), which activates 
phospholipase A2 and ensures a replete supply of arachidonic acid is available for 
COX enzymes. After a further 30 mins, supernatant was removed for measurement of 
PGE2 levels by immunoassay (Cisbio, France). This assay time is sufficient to allow 
the activity of COX enzymes to be measured but short enough that no confounding 
effects on COX gene expression are likely to occur. 
 
Tissue PGE2, prostacyclin, cAMP and cGMP measurement  
Levels of PGE2, prostacyclin (as its spontaneous breakdown product; 6-keto-PGF1α) 
cAMP and cGMP were determined in homogenates of renal medulla and/or spleen of 
mice treated with parecoxib in vivo as above. Tissue was homogenised using a 
Precellys24 TissueLyser (Stretton Scientific, UK) in 20x volume of PBS containing 
diclofenac (100μM; Sigma, UK) to block prostaglandin formation during 
homogenisation, isobutylmethyxanthine (0.5mM; Sigma, UK) to prevent cAMP/cGMP 
degradation during homogenisation and a protease inhibitor cocktail (1X; Roche 
Applied Bioscience, UK) to prevent general protein breakdown. The homogenates 
where then separated by centrifugation and the levels of PGE2 (Cisbio, France), cAMP 
(Cisbio, France), cGMP (Cisbio, France) and 6-keto-PGF1α (Enzo Lifescience, USA) 
were measured in the supernatant by immunoassay. 
 
Myography  
Thoracic aorta and renal artery were carefully dissected and cleaned of peri-adventitial 
material. 2mm rings of each vessel were mounted in organ baths of an isometric wire 
myograph (Danish Myo Technology, Demark). Vessels were bathed in Krebs buffer 
bubbled with 95% O2/5% CO2 and heated to 37°C and a resting tension of 6-8mN 
applied. To determine the contribution of endogenous COX activity to vascular 
responsiveness, vessels were incubated with diclofenac (3μM, 30 mins; Sigma, UK) 
to block all COX-1 and COX-2 activity and therefore remove all endogenous 
prostanoid production. To do this, it was necessary to apply phenylephrine (10nM-
10μM; Sigma, UK) to the vessels to produce a contractile response as isolated vessels 
do not spontaneously develop tone. In the same vessels, the effect of endogenous 
prostaglandins was then measured. For this protocol, vessels were washed and 
treated with diclofenac to block endogenous prostanoids before being pre-contracted 
with an EC50 concentration of phenylephrine. Cumulative responses were then 
recorded to the EP receptor agonist, PGE2 (Sigma, UK), the mixed IP/PPARβ/δ 
agonist prostacyclin-mimetic, treprostinil (Cayman Chemical, USA), the selective IP 
agonist, MRE269 (Cayman Chemical, USA) or the selective PPARβ/δ agonist, 
GW0742 (R&D Systems, UK). Responses were measured using LabChart 4 software 
(AD Instruments, UK). Responses to exogenous prostanoid drugs were normalised as 
a percentage of the pre-existing contraction as is convention for dilator responses. 
 
Tissue slice preparation and imaging of vascular responses  
Vascular responses in precision cut tissue slices were measured essentially as we 
have previously performed in lung11, 12. Precision-cut slices of intact mouse kidney 
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(~150μm thick) were prepared using a Krumdieck Tissue Slicer (Alabama Research, 
USA). Kidney slices were left to equilibrate at 37°C for 1 hour during which arcuate 
arteries were identified by microscopy based on their location at the boundary of cortex 
and medulla and relationship with attached veins. To measure vascular responses, in 
slices bathed in Krebs buffer at 37°C, individual arteries were focused at 5X objective 
magnification under a video microscope (Zeiss, Germany). To determine the 
contribution of endogenous COX-1- and COX-2-derived prostanoids and the PPARβ/δ 
receptor in vascular responses, slices were pre-treated with non-selective COX-
1/COX-2 inhibitor, diclofenac (3μM), the selective COX-2 inhibitor, valdecoxib (3μM; 
Sigma, UK) the selective COX-1 inhibitor, SC560 (100nM; Sigma, UK) and/or the 
selective PPARβ/δ antagonist GSK3787 (3μM; Sigma, UK) for 30 mins and then 
cumulative response curves to phenylephrine measured (30nM-10μM). To determine 
the sensitivity of these vessels of exogenous prostanoids, in separate slices, after 
treatment with diclofenac to block all endogenous COX activity, arteries were pre-
contracted with an EC50 concentration of phenylephrine, and cumulative responses to 
PGE2 (EP receptor agonist) treprostinil (mixed IP/PPARβ/δ agonist prostacyclin-
mimetic), MRE269 (selective IP agonist) or GW0742 (selective PPARβ/δ agonist) 
measured. Vessel diameter was quantified by tracing their outline in single video 
frames using ImageJ software (NIH, USA). Constrictor responses were normalised as 
a percentage of the initial vessel diameter and dilator responses as a percentage of 
the pre-contraction as is convention of vascular response data. 
 
Prostaglandin release  
To measure prostaglandin levels from renal and aortic tissue where it is not possible 
to obtain comparable homogenates due to the differences in tissue volumes, intact 
segments of tissues segments (2x2x2mm) were used. Tissue pieces were placed 
DMEM media (Sigma, UK) containing A23187 Ca2+ ionophore (30μM) for 30 mins at 
37°C. A23187 activates phospholipase A2 and in so doing ensures that there is replete 
arachidonic acid available and removes this as a limiting factor for observing the 
relative COX activity and prostaglandin production. PGE2 and prostacyclin (measured 
as 6-keto-PGF1α) were measured in the conditioned media by immunoassay (Cayman 
Chemical, USA). This method only applies to the data in Figure S3 as in all other 
figures, prostanoids were measured in tissue homogenates without stimulation. 
  
qPCR  
Gene expression in renal and aortic tissue was measured by quantitative reverse-
transcriptase PCR. RNA was extracted from tissue homogenates using an RNeasy 
Mini kit (Qiagen, UK) and converted to cDNA using reverse transcriptase (Fermantas, 
UK) and oligo(dT) primers (Life Technologies, UK). Expression of Ptgir (IP receptor; 
probe ID: Mm00801939_m1), Ptger1 (EP1 receptor; probe ID: Mm00443098_g1), 
Ptger2 (EP2 receptor; probe ID: Mm00436051_m1), Ptger3 (EP3 receptor; probe ID: 
Mm01316856_m1) Ptger4 (EP4 receptor; probe ID: Mm00436053_m1) and Ppard 
(PPARβ/δ; probe ID: Mm00803184_m1) were then measured using TaqMan gene 
expression assays (Life Technologies, UK), qPCR master mix (Fermenstas, UK) and 
an Applied Biosystems (UK) 7500 Fast instrument. Data were normalised to 
expression of housekeeping genes 18s (probe ID: Mm0392899_g1) and Gapdh 
(probe ID: Mm99999915_g1) using the comparative CT method. 
 
Statistics and data analysis  
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Data are presented as means ± standard errors for n experiments. Myography and 
vessel imaging data sets were normalised as described above. All data were 
statistically analysed using Prism 7 software (Graphpad Software, USA) as defined in 
individual figure legends – typically either Student’s unpaired t-test for in vivo data or 
two-way ANOVA for vascular response data. Differences were considered statistically 
significant where p<0.05.  
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Tissue/Region Blood flow (ml/min/g) p 
Basal Saline 
Skeletal Muscle 0.3 ± 0.0 0.3 ± 0.2 0.81 
Bone 0.4 ± 0.1 0.7 ± 0.4 0.28 
Hippocampus 0.5 ± 0.1 0.6 ± 0.1 0.61 
Thymus 0.5 ± 0.1 0.8 ± 0.3 0.27 
Trachea 0.5 ± 0.1 0.4 ± 0.1 0.47 
Skin 0.5 ± 0.1 0.7 ± 0.2 0.43 
Stomach 0.6 ± 0.1 0.1 ± 0.0 0.02 * 
Testes 1.3 ± 0.2 1.3 ± 0.1 1.00 
Bladder 1.3 ± 0.2 0.9 ± 0.3 0.32 
Adipose Tissue 1.5 ± 0.4 2.0 ± 0.2 0.45 
Mesentery 1.9 ± 0.3 2.0 ± 0.3 0.86 
Ileum 2.0 ± 0.3 2.6 ± 0.7 0.40 
Brain Stem 2.3 ± 0.5 0.7 ± 0.1 0.06 
Colon 2.4 ± 0.5 1.6 ± 0.4 0.34 
Renal Medulla 2.6 ± 0.5 2.2 ± 0.8 0.63 
Spleen 3.6 ± 0.8 2.3 ± 0.4 0.30 
Cerebellum 4.9 ± 0.8 2.9 ± 0.1 0.21 
Cerebral Cortex 5.4 ± 1.1 3.0 ± 0.5 0.21 
Heart 10.6 ± 1.8 7.4 ± 1.0 0.30 
Renal Cortex 10.9 ± 1.3 9.2 ± 1.0 0.45 
Duodenum 13.3 ± 1.6 9.0 ± 1.5 0.13 
 
Table S1: Effect of saline bolus on regional blood flow. Data are presented as mean ± 
standard error. *, p<0.05 by Student’s unpaired t-test. n=4-10. 
 
 
 
 
Measurement (units) PPARβ/δ+/+ PPARβ/δ-/- p 
PGE2 levels (ng/g tissue) 3.4 ± 0.7 2.8 ± 0.7 0.53 
6ketoPGF1ɑ levels (ng/g tissue) 5.9 ± 1.2 4.8 ± 1.1 0.52 
Ptgs2 expression (fold-difference) 1.0 ± 0.8 1.1 ± 0.3 0.93 
Ptger1 expression (fold-difference) 1.0 ± 0.5 1.1 ± 0.2 0.83 
Ptger2 expression (fold-difference) 1.0 ± 0.6 0.8 ± 0.2 0.75 
Ptger3 expression (fold-difference) 1.0 ± 0.6 1.6 ± 0.2 0.31 
Ptger4 expression (fold-difference) 1.0 ± 0.7 2.0 ± 0.3 0.21 
Ptgir expression (fold-difference) 1.0 ± 0.5 0.7 ± 0.1 0.46 
 
Table S2: Effect of PPARβ/δ deletion on prostanoid production and expression of COX-
2 and prostanoid receptors in the renal medulla. Data are presented as mean ± standard 
error. p values by Student’s unpaired t-test. n=3-7. 
 
 9
  
Figure S1: Inhibitory activity of plasma from mice treated with parecoxib in vivo on 
COX-1 (a) and COX-2 (b) activity ex vivo. COX-1 inhibitory activity bioassayed as PGE2 
production by segments of lung from Cox2-/- mice. COX-2 inhibitory activity bioassayed as 
PGE2 production from J774 murine macrophages treated with LPS (10μg/ml) to induce COX-
2. Data are presented as mean ± standard error. *, p<0.05 by Student’s unpaired t-test. n=5-
6. 
 
 
 
 
 
 
 
 
  
Figure S2: Effect of selective COX-1 inhibition on contractile responses of intra-renal 
arcuate arteries. Contractile responses to phenylephrine were studied in intra-renal arcuate 
arteries by imaging in precision-cut kidney slices after incubation with the selective COX-1 
inhibitor SC560 (100nM). *, p<0.05 by two-way ANOVA. n=4-6. 
 
 
  
 10
  
Figure S3: Prostanoid production (a) and receptor expression profile (b) in renal and 
vascular tissue. Prostacyclin and PGE2 production were measured by immunoassay in 
supernatants after incubation with intact sections of renal medulla, renal cortex or aorta. 
Expression of the genes encoding the IP receptor (Ptgir) or PPARβ/δ (Ppard) were measured 
by qPCR and expressed at ΔCT after correction for 18s and Gapdh expression (lower value = 
higher expression). n=3-4.  
 
 
 
 
 
 
 
  
Figure S4: Effect of specific IP and PPARβ agonists on vascular tone in aorta (a) and 
renal arteries (b). Responses to the IP agonist MRE269 and PPARβ agonist GW0742 in 
phenylephrine pre-contracted aorta and renal arteries studied by wire myography. *, p<0.05 
by one-way ANOVA. n=4-5.  
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Figure S5: Schematic for regulation of renal blood flow by NFAT-mediated constitutive 
COX-2 expression, prostacyclin (PGI2) and PPARβ/δ.  
 
 
 
 
